Elsevier

The Lancet

Volume 325, Issue 8440, 1 June 1985, Pages 1233-1236
The Lancet

COMPARISON OF WEIGHT REDUCTION WITH METOPROLOL IN TREATMENT OF HYPERTENSION IN YOUNG OVERWEIGHT PATIENTS

https://doi.org/10.1016/S0140-6736(85)92310-4Get rights and content

Abstract

Weight reduction was compared with metoprolol (200 mg daily) in a randomised placebo-controlled trial of first-line treatment of mild hypertension (diastolic blood pressure 90-109 mm Hg) in 56 overweight patients aged under 55 years. After 21 weeks of follow up the weight-reduction group had lost an average of 7·4 kg. The fall in their systolic pressure of 13 mm Hg was significantly greater than that in the placebo group (7 mm Hg) but not different from that in the metoprolol group (10 mm Hg). Their fall in diastolic pressure (10 mm Hg) was greater than that in both the metoprolol (6 mm Hg) and placebo (3 mm Hg) groups. At the end of the follow-up period 50% of patients in the weight-reduction group had a diastolic pressure of less than 90 mm Hg. In the metoprolol group there was a decrease in high density lipoprotein (HDL)-cholesterol and an increase in the ratio of total to HDL-cholesterol; in the weight-reduction group there was a decrease both in total cholesterol and in the ratio of total to HDL-cholesterol. Thus in this study population weight reduction produced significant and clinically important reductions in blood pressure but not the adverse effects on plasma lipids commonly associated with antihypertensive drug therapy.

References (19)

There are more references available in the full text version of this article.

Cited by (123)

  • The Impact of Obesity on the Pharmacology of Medications Used for Cardiovascular Risk Factor Control

    2015, Canadian Journal of Cardiology
    Citation Excerpt :

    Most studies were single-dose or short-term studies, limiting the conclusions that can be made regarding long-term therapy. These studies have examined agents ranging in lipophilicity from lipophilic (propranolol,23,24,39-42 metoprolol,43,44 nebivolol,41,45), intermediate (bisoprolol46), and hydrophilic (atenolol,43,47 sotalol24; Supplemental Table S1). There is considerable intrastudy variation in terms of the effect of obesity on different pharmacokinetic parameters.

  • Obesity and Hypertension: Mechanisms, Cardio-Renal Consequences, and Therapeutic Approaches

    2009, Medical Clinics of North America
    Citation Excerpt :

    The antihypertensive efficacy of beta blockers in obese patients remains controversial. Small studies have shown that metoprolol was not effective in controlling blood pressure,105 whereas atenolol showed a beneficial effect.106 Consequently, the classic beta blockers are not recommended in obese patients for the control of blood pressure.

  • Obesity in Hypertension

    2007, Hypertension: A Companion to Braunwald's Heart Disease
  • Controversies in hypertension

    2006, Lancet
    Citation Excerpt :

    Nevertheless, such calorie-reduced diets might (if adhered to) modify cardiovascular risk factors, including blood-pressure reduction. Notably, in two studies, diet combined with sodium restriction successfully reduced blood pressure, with a greater decrease at 21 weeks19 than at 52 weeks.20 Orlistat treatment for 4 years, together with lifestyle modifications, reduced bodyweight by 5% and blood pressure by 4·9/2·6 mm Hg (from initial values of 130·8/82·0 mm Hg), compared with a fall of 3·5/1·9 mm Hg with lifestyle alone (p<0·01).21

View all citing articles on Scopus
1

Present address: Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Heart Lung and Blood Institute, National Institutes of Health, Maryland, USA.

View full text